Impaired Levodopa Response in Parkinsonʼs Disease During Melanoma Therapy

Merello, Marcelo; Esteguy, M.; Perazzo, Florencia; Leiguarda, R

doi:10.1097/00002826-199202000-00010

Cited by 12 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neurological adverse events that may occur after exposure to these drugs include encephalopathy, seizures, peripheral neuropathy, and cranial nerve dysfunction 1–4. A few reports have described de novo parkinsonism5–13 or worsening of preexisting Parkinson's disease14–16 after exposure to chemotherapy. In some cases, a single agent is responsible, whereas in others, multiple drugs are likely involved, especially in association with bone marrow transplantation 7–9.…”

mentioning

confidence: 99%

Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity

et al. 2002

View full text Add to dashboard Cite

Parkinsonism is a rare neurological complication of cancer treatment. Although individual case reports of this syndrome have been reported, the clinical features and prevalence of this syndrome are unknown. We present 3 patients, encountered over 6 months at one institution, who developed parkinsonism after treatment with various chemotherapeutic agents. Parkinsonism was severe in 2 patients, affecting postural reflexes, speech, and swallowing. All 3 patients responded dramatically to treatment with levodopa, and parkinsonism spontaneously improved or remitted over months. This unusual complication of cancer therapy is treatable and may be underappreciated.

show abstract

mentioning

confidence: 99%

Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity

et al. 2002

View full text Add to dashboard Cite

show abstract

“…In rodent models, it has been shown to exhibit antioxidant and anti-inflammatory effects ( 224 ). Interestingly, a PD patient’s response to levodopa improved while receiving dacarbazine as part of their treatment for melanoma ( 225 ). However, dacarbazine has also been shown to cause mitochondrial dysfunction and promote oxidative stress in rat hepatocytes ( 226 ).…”

Section: Discussionmentioning

confidence: 99%

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease

Miller,

Darji,

Walaieh

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

Drosophila melanogaster is a valuable model organism for a wide range of biological exploration. The well-known advantages of D. melanogaster include its relatively simple biology, the ease with which it is genetically modified, the relatively low financial and time costs associated with their short gestation and life cycles, and the large number of offspring they produce per generation. D. melanogaster has facilitated the discovery of many significant insights into the pathology of Parkinson’s disease (PD) and has served as an excellent preclinical model of PD-related therapeutic discovery. In this review, we provide an overview of the major D. melanogaster models of PD, each of which provide unique insights into PD-relevant pathology and therapeutic targets. These models are discussed in the context of their past, current, and future potential use for studying the utility of secondary metabolites as therapeutic agents in PD. Over the last decade, senolytics have garnered an exponential interest in their ability to mitigate a broad spectrum of diseases, including PD. Therefore, an emphasis is placed on the senolytic and senomorphic properties of secondary metabolites. It is expected that D. melanogaster will continue to be critical in the effort to understand and improve treatment of PD, including their involvement in translational studies focused on secondary metabolites.

show abstract

“…Trismus is a complication associated with head and neck radiotherapy (2). Several factors may have caused trismus in this patient: temporomandibular joint (TMJ) fibrosis, myokymia, and muscle spasms.…”

mentioning

confidence: 84%

Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma

Bower

Muenter

1995

Movement Disorders

View full text Add to dashboard Cite

Impaired Levodopa Response in Parkinsonʼs Disease During Melanoma Therapy

Cited by 12 publications

References 0 publications

Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity

Chemotherapy‐induced parkinsonism responsive to levodopa: An underrecognized entity

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease

Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma

Contact Info

Product

Resources

About